Prestige Consumer Healthcare (PBH) Bets Big On M&A, But Can Clear Eyes Recover?
Prestige Consumer Healthcare (NYSE:PBH) closed two acquisitions within three weeks this summer, adding roughly $240 million in annualized revenue to a portfolio anchored by Dramamine and Compound W.






